ClinicalTrials.gg
CompletedNCT00858234Updated Apr 9, 2021Results posted

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

A Phase 1 interventional study of Vorinostat and Bortezomib in Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.

Enrollment
14th of 17
9 · median 31
Started
2009
with 2 others
Phase 1
10 of 19
none open now
Registered
12th of 19
by date
Lead sponsor
6 of 19
Merck Sharp & Dohme LLC

Among the 19 studies testing vorinostat in Multiple Myeloma, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2009, is one of 10 in phase 1, and was the 12th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing vorinostat in Multiple Myeloma as a file.
02

Study summary

The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refractory multiple myeloma (MM). It was hypothesized that administration of vorinostat in combination with bortezomib is sufficiently safe and tolerated well enough to permit further study in participants with relapsed and/or refractory MM. Study results are based on data collected up to the data cut-off date of 20-March-2011.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is ≥20 years of age.
  • has an established diagnosis of MM based on the myeloma diagnostic criteria
  • has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen
  • has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • has had a prior bone marrow transplant or plans to undergo any type of bone marrow transplantation during the study
  • has known to any components of vorinostat or bortezomib
  • has active or C, plasma cell leukemia, or is (HIV) positive
  • has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Vorinostat + Bortezomib

    Participants undergo up to 3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg once daily \[QD\] on Days 1 through 14) + bortezomib (1.3 mg/m\^2 intravenous \[IV\] on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\^2 IV on Days 1, 4, 8, and 11).

    Drug: Vorinostat · Drug: Bortezomib

Interventions

  • Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.

    Also known as: MK-0683, ZOLINZA™

  • Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.

    Also known as: VELCADE®

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1

    The number of participants with ≥1 DLT during Cycle 1 is reported. A DLT is defined as an event considered by the investigator to be related to study treatment, and either: 1) a Grade 3 or 4 non-hematologic event (except for manageable toxicity by supportive care or non-prohibited therapies, or a transient increase in alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]); or 2) a Grade 4 hematologic toxicity except neutropenia or hemoglobin decreased (neutropenia was a DLT if it was Grade 3-4 with fever ≥38.5°C; Grade 3-4 with an infection requiring antibiotic/antifungal therapy; or Grade 4 and lasting ≥5 days).

    Time frame: Up to 21 days

Other outcomes

  1. Number of Participants With an Adverse Event (AE)

    The number of participants with ≥1 AE is reported. An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product(s), whether or not considered related to the use of the product(s).

    Time frame: Up to 346 days (up to 30 days after the final dose of study treatment)

  2. Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11

    The AUC0-24hr of vorinostat in plasma on Days 1 and 11 is reported in participants who also received bortezomib.

    Time frame: Predose and 0.8, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 1 and 11

07

Results

Posted Apr 9, 2021

Participant flow

Adult male and female participants with relapsed and/or refractory multiple myeloma (MM) were enrolled at study sites in Japan.

Participant flow — Overall Study
MilestoneVorinostat + Bortezomib
Started9
Completed0
Not completed9
Withdrew: Adverse event6
Withdrew: Progressive disease2
Withdrew: Status unknown1

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1

The number of participants with ≥1 DLT during Cycle 1 is reported. A DLT is defined as an event considered by the investigator to be related to study treatment, and either: 1) a Grade 3 or 4 non-hematologic event (except for manageable toxicity by supportive care or non-prohibited therapies, or a transient increase in alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]); or 2) a Grade 4 hematologic toxicity except neutropenia or hemoglobin decreased (neutropenia was a DLT if it was Grade 3-4 with fever ≥38.5°C; Grade 3-4 with an infection requiring antibiotic/antifungal therapy; or Grade 4 and lasting ≥5 days).

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1
ParticipantsVorinostat + Bortezomib
Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 11
Other pre-specifiedNumber of Participants With an Adverse Event (AE)

The number of participants with ≥1 AE is reported. An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product(s), whether or not considered related to the use of the product(s).

Time frame:
Up to 346 days (up to 30 days after the final dose of study treatment)
Reported as:
Count of participants · Participants
Number of Participants With an Adverse Event (AE)
ParticipantsVorinostat + Bortezomib
Number of Participants With an Adverse Event (AE)9
Other pre-specifiedArea Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11

The AUC0-24hr of vorinostat in plasma on Days 1 and 11 is reported in participants who also received bortezomib.

Time frame:
Predose and 0.8, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 1 and 11
Reported as:
Least squares mean · µM*hr
Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11
µM*hrVorinostat + Bortezomib
Day 15.41 (4.33 to 6.77)
Day 115.84 (4.48 to 7.61)
Statistical analysis
  • Vorinostat + Bortezomib · Accumulation ratio: 1.08 · 90% CI 0.80 to 1.45Back-transformed least squares mean difference and 90% confidence interval from mixed effects model performed on natural log-transformed values.

Adverse events

Collected over Up to 346 days (up to 30 days after the final dose of study treatment). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat + Bortezomib0/9 (0%)3/9 (33.3%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventVorinostat + Bortezomib
PneumoniaInfections and infestations2/9
Disseminated intravascular coagulationBlood and lymphatic system disorders1/9
FatigueGeneral disorders1/9
PyelonephritisInfections and infestations1/9
SepsisInfections and infestations1/9
Decreased appetiteMetabolism and nutrition disorders1/9
Most frequent other events
Showing 10 of 74
Most frequent other events
EventVorinostat + Bortezomib
LeukopeniaBlood and lymphatic system disorders9/9
NeutropeniaBlood and lymphatic system disorders9/9
ThrombocytopeniaBlood and lymphatic system disorders9/9
DiarrhoeaGastrointestinal disorders9/9
NauseaGastrointestinal disorders8/9
Decreased appetiteMetabolism and nutrition disorders8/9
VomitingGastrointestinal disorders7/9
LymphopeniaBlood and lymphatic system disorders6/9
ConstipationGastrointestinal disorders6/9
FatigueGeneral disorders5/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Vorinostat + Bortezomib
Mean63.3 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat + Bortezomib
Female1
Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vorinostat + Bortezomib
American Indian or Alaska Native0
Asian9
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Ogawa Y, Ogura M, Tobinai K, Ando K, Suzuki T, Watanabe T, Ohmachi K, Uchida T, Hanson ME, Tanaka Y, Koh Y, Shimamoto T, Hotta T. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 2016 Jan;103(1):25-33. doi: 10.1007/s12185-015-1897-7. Epub 2015 Nov 30. PubMed 26619834 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Jun 2010, 15 months.

Results were first posted in Apr 2021, 10 years 9 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 15 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2009
First posted
Mar 9, 2009
StartActual
Feb 13, 2009
Primary completionActual
Jun 11, 2010
CompletionActual
Apr 19, 2012
Results first posted
Apr 9, 2021
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00858234
Responsible party
Sponsor
First posted
Mar 9, 2009
Start date
Feb 13, 2009
Primary completion
Jun 11, 2010
Completion
Apr 19, 2012
Results posted
Apr 9, 2021
Last update
Apr 9, 2021

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vorinostat · Bortezomib

Start the discussion